Efficacy, safety and tolerability of the CCR1 antagonist BAY 86‐5047 for the treatment of endometriosis‐associated pelvic pain: a randomized controlled trial

Dietmar Trummer, Anja Walzer, Esther Groettrup-Wolfers, Esther Groettrup‐Wolfers, Heinz Schmitz, H. Schmitz
Acta obstetricia et gynecologica Scandinavica · 2017 · vol. 96(6) , pp. 694–701 · doi:10.1111/aogs.13105 · PMID:28168715 · W2586202643
article OA: bronze CC0 ⤵ 4 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher

Abstract

INTRODUCTION: Antagonism of CC chemokine receptor type 1 (CCR1) may provide a novel treatment approach for women with symptomatic endometriosis. Studies of CCR1 antagonists in these patients have not been reported. MATERIAL AND METHODS: Women (n = 110; 18-45 years) with symptomatic endometriosis were randomized to BAY 86-5047 or placebo for 12 weeks. Pelvic pain was assessed using the visual analogue scale (VAS) and women recorded the intake of pain medication in a diary. The primary efficacy outcome was a composite of the absolute change in VAS score and the cumulative change in consumption of analgesics between baseline and the end of treatment. Safety assessments included adverse events, blood and urine evaluation and electrocardiography. RESULTS: Mean VAS scores decreased from 64.8 mm at baseline to 49.2 mm at week 12 in the BAY 86-5047 group and from 67.2 mm to 47.8 mm in the placebo group. The proportion of women using analgesics decreased from 33.9% to 11.5% or from 44.4% to 15.4% for patients who received BAY 86-5047 or placebo, respectively. There was no significant difference between the two treatment groups in terms of change in VAS scores (p = 0.45) or intake of analgesics (p = 0.82). A three-step sensitivity analysis failed to show superiority of BAY 86-5047 over placebo (p = 0.67). BAY 86-5047 was well tolerated and no significant safety concerns arose during the study. CONCLUSIONS: Based on these results, BAY 86-5047 is unlikely to be useful in the treatment of women with endometriosis-associated pelvic pain.

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Pelvic Pain Receptors, CCR1 Adult Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Endometriosis Endometriosis Female Humans Pain Measurement Pelvic Pain Pelvic Pain Receptors, CCR1 Receptors, CCR1 Treatment Outcome Young Adult

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Cited by (4)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:37.704673+00:00
License: CC0 · commercial use OK